In Vitro COPD Risk Evaluation Using Gene Expression Analysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack an effective, statistically quantitative approach to evaluate the risk of chronic obstructive pulmonary disease (COPD) associated with smoking or inhalation, particularly for heated tobacco products, as existing techniques fail to accurately assess the disease risk from fluctuations in gene expression levels caused by biologically active chemical substances.
Innovation Solution
An in vitro method using microarray data and logistic regression analysis to calculate probabilities based on gene expression in airway epithelial cells exposed to aerosols from heated tobacco products, specifically utilizing genes like TXNIP, EFNA1, ADM, SLC7A11, and others to determine the potential COPD risk (PRF) by normalizing gene expression data and applying intercepts and coefficients calculated in advance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional single exposure tests on monolayer cultured cells are used, then the test simplicity is maintained, but the extrapolation accuracy to humans is insufficient
Solution Approach 1:
The patent transitions from static monolayer cell cultures to dynamic three-dimensional tissue models that better replicate in vivo conditions. The air-liquid interface culture system creates a more physiologically relevant environment, improving extrapolation accuracy while managing complexity through standardized protocols
Solution Approach 2:
The patent moves from two-dimensional monolayer cultures to three-dimensional tissue models, adding spatial dimensionality to better represent human airway epithelium structure. This dimensional transition significantly improves the biological relevance and extrapolation accuracy of the test results
2Object-generated harmful factors
If heated tobacco products are used, then the generation of chemical substances from burning is suppressed, but the lack of established evaluation techniques for disease risk remains
Solution Approach 1:
The patent replaces traditional combustion-based smoking with heated tobacco products that use thermal energy instead of chemical combustion. This substitution reduces the generation of harmful chemical substances while the accompanying evaluation method provides the needed disease risk assessment capability
Solution Approach 2:
The patent changes the fundamental parameter of temperature application - using controlled heating at lower temperatures (avoiding combustion) versus high-temperature burning. This parameter change reduces harmful chemical generation while the gene expression evaluation method enables precise disease risk assessment of the new product type
3Measurement precision
If gene expression data is collected without normalization, then the data collection process is simpler, but the statistical evaluation accuracy is reduced
Solution Approach 1:
The patent performs gene expression data normalization as a preliminary step before statistical analysis. This preliminary action standardizes the data from multiple samples and conditions, ensuring accurate statistical evaluation while the automated normalization protocols manage the processing complexity
Data Source
AI summary
The present invention relates to an in vitro method for evaluating the risk of chronic obstructive pulmonary disease associated with smoking or inhalation. The method of the present invention comprises: (1) calculating probability PSMK on the basis of data on the expression of 11 or more genes including at least 11 specific genes from among the following 15 genes in airway epithelial cells exposed to a sample solution containing an aerosol or particulate matter in the aerosol from a tobacco product: TXNIP, EFNA1, CYP1 B1, ADM, AREG, DUSP6, SLC7A11, IGFBP3, WNT5A, CXCR4, PHLDA1, HILPDA, ZBED2, EGLN3, and FBXO32, with use of an intercept and coefficients calculated in advance by logistic regression analysis using public data; (2) calculating probability PCOPD on the basis of data on the expression of 4 or more genes including at least 4 specific genes from among the following 15 genes in airway epithelial cells exposed to a sample solution containing the an aerosol or particulate matter in the aerosol from a tobacco product, with use of coefficients calculated in advance by logistic regression analysis using public data; and (3) calculating the risk of chronic obstructive pulmonary disease associated with smoking or inhalation of the aerosol or particulate matter in the aerosol from the tobacco product from the probability PSMK and the probability PCOPD.